Ndyomugyenyi 2000 UGA.

Methods	Trial design: RCT Data collected: 1996 to 1998 Length of follow‐up: from first antenatal visit to first week postpartum Frequency of follow‐up: monthly
Participants	Parity: 0 Number: 860 Inclusion criteria: primigravidae Excluded: severe anaemia (< 8 g)
Interventions	1. Chloroquine 2. Placebo 3. Iron + folate (not included in the analysis) Other: clinical malaria symptoms treated with 25 mg/kg of chloroquine for three days, ITNs Administration supervised: no
Outcomes	1. Haemoglobin 2. Birthweight
Notes	Location: Uganda Urban/rural: rural (Hoima District) Malaria transmission: hyperendemic area Drug resistance: unknown Funding: The Danish Bilharziasis Laboratory, Denmark
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	"After clinical and laboratory examination, women were randomly assigned to 1 of the 3 intervention group". Insufficient details.
Allocation concealment (selection bias)	Unclear risk	No information provided.
Blinding (performance bias and detection bias) All outcomes	Low risk	Placebo and active tablets of the same colour and shape.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	No information provided to make a judgement whether or not the outcome assessors were blinded.
Incomplete outcome data (attrition bias) All outcomes	High risk	A high attrition rate of 32.6% (268 out of 823 women were lost to follow‐up).
Selective reporting (reporting bias)	Low risk	No apparent risk.
Other bias	Low risk	None identified.